Literature DB >> 10386821

A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations.

B D Anawalt1, R A Bebb, W J Bremner, A M Matsumoto.   

Abstract

Studies using exogenous high-dosage testosterone (T) or a combination regimen of physiologic T plus high-dosage levonorgestrel (LNG) administration in normal men have shown that oligoazoospermia (<3 million/mL) or azoospermia can be achieved in the majority of the men. However, these hormonal regimens have been associated with significant weight gain and suppression of serum high-density lipoprotein (HDL) cholesterol levels. We hypothesized that a combination of physiologic exogenous testosterone and lower dosage LNG would result in uniform severe oligoazoospermia or azoospermia in normal men but would cause fewer adverse metabolic side effects. We conducted a randomized, placebo-controlled, single-blind trial comparing 6 months of T enanthate (100 mg IM, weekly) plus LNG, 125 microg by mouth, daily (LNG 125; n = 18) or LNG, 250 microg by mouth, daily (LNG 250; n = 18) and compared these regimens with our previous study of the same dosage of T enanthate combined with placebo LNG (LNG 0; n = 18) or with 500 mg of LNG (LNG= 500; n = 18). All three combination regimens of T enanthate and LNG suppressed spermatogenesis more rapidly and resulted in significantly more uniform severe oligoazoospermia (<1 million/mL) than the T-alone regimen. Severe oligoazoospermia was achieved in 89% of the LNG 125, 89% of the LNG 250, and 78% of the LNG 500 groups, respectively, versus 56% of the men in LNG 0 (P < 0.05 for the combination groups vs. LNG 0), but there were no significant differences between the combination regimens (P = NS). All four groups gained significant weight compared with their baselines, although the gain tended to be greater as the dosage of LNG increased (2.0+/-0.9, 2.9+/-1.1, 3.6+/-1.0, and 5.4+/-1.0 kg gained, compared with baseline in the LNG 0, 125, 250, and 500 groups respectively; P < 0.05 compared with baseline). Serum levels of HDL cholesterol decreased in all of the groups, but the effect was larger as the dosage of LNG increased (4+/-4% vs. 13+/-4%, 20+/-3%, and 22+/-4% decrease in HDL levels from baseline in the LNG 0, LNG 125, LNG 250, and LNG 500 groups respectively; P = 0.06 for LNG 125 compared with LNG 0, and P < 0.05 for LNG 250 and LNG 500 compared with LNG 0). We conclude that 1) the combination of physiologic exogenous T enanthate and LNG suppresses spermatogenesis more effectively than T enanthate alone and that 2) the combination regimen of T enanthate plus lower dosage LNG suppresses sperm production comparably to T enanthate plus higher dosage LNG, while causing less weight gain and HDL cholesterol suppression. A combination regimen of physiologic testosterone plus a low dosage of levonorgestrel offers great promise as a safe and effective male contraceptive regimen.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10386821

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  16 in total

1.  Complete sperm suppression in rats with dienogest plus testosterone undecanoate is facilitated through apoptosis in testicular cells.

Authors:  Rekha Meena; Man Mohan Misro; Debidas Ghosh
Journal:  Reprod Sci       Date:  2012-11-30       Impact factor: 3.060

2.  Androgen synthesis in the gonadotropin-suppressed human testes can be markedly suppressed by ketoconazole.

Authors:  M Y Roth; J J S Nya-Ngatchou; K Lin; S T Page; B D Anawalt; A M Matsumoto; B T Marck; W J Bremner; J K Amory
Journal:  J Clin Endocrinol Metab       Date:  2013-01-24       Impact factor: 5.958

Review 3.  Continuing the search for a hormonal male contraceptive.

Authors:  Fiona Yuen; Brian T Nguyen; Ronald S Swerdloff; Christina Wang
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2020-02-19       Impact factor: 5.237

4.  Effect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard gel: a randomized, cross-over, pharmacokinetic study.

Authors:  Vivian Brache; Horacio Croxatto; Narender Kumar; Regine Sitruk-Ware; Leila Cochón; Veronica Schiappacasse; Irving Sivin; Carla Muñoz; Robin Maguire; Anibal Faundes
Journal:  Contraception       Date:  2008-11-21       Impact factor: 3.375

Review 5.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 6.  Beyond the Condom: Frontiers in Male Contraception.

Authors:  Mara Y Roth; John K Amory
Journal:  Semin Reprod Med       Date:  2016-03-04       Impact factor: 1.303

7.  Effects of 28 Days of Oral Dimethandrolone Undecanoate in Healthy Men: A Prototype Male Pill.

Authors:  Arthi Thirumalai; Jonas Ceponis; John K Amory; Ronald Swerdloff; Vijaya Surampudi; Peter Y Liu; William J Bremner; Eric Harvey; Diana L Blithe; Min S Lee; Laura Hull; Christina Wang; Stephanie T Page
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

8.  Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis.

Authors:  Peter Y Liu; Ronald S Swerdloff; Bradley D Anawalt; Richard A Anderson; William J Bremner; Joerg Elliesen; Yi-Qun Gu; Wendy M Kersemaekers; Robert I McLachlan; M Cristina Meriggiola; Eberhard Nieschlag; Regine Sitruk-Ware; Kirsten Vogelsong; Xing-Hai Wang; Frederick C W Wu; Michael Zitzmann; David J Handelsman; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2008-02-26       Impact factor: 5.958

Review 9.  Male hormonal contraception: looking back and moving forward.

Authors:  M Y Roth; S T Page; W J Bremner
Journal:  Andrology       Date:  2015-10-09       Impact factor: 3.842

10.  A new combination of testosterone and nestorone transdermal gels for male hormonal contraception.

Authors:  Niloufar Ilani; Mara Y Roth; John K Amory; Ronald S Swerdloff; Clint Dart; Stephanie T Page; William J Bremner; Regine Sitruk-Ware; Narender Kumar; Diana L Blithe; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2012-07-12       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.